{"id":"carmofur","rwe":[{"pmid":"41235136","year":"2025","title":"PSORI-CM02 Restores Epidermal Differentiation in Psoriasis via the Gut Microbiota-Sphingolipid Axis.","finding":"","journal":"Drug design, development and therapy","studyType":"Clinical Study"},{"pmid":"40705936","year":"2025","title":"Reproducibility of QM/MM Calculations for the SARS-CoV-2 Main Protease.","finding":"","journal":"Journal of chemical theory and computation","studyType":"Clinical Study"},{"pmid":"40702551","year":"2025","title":"Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.","finding":"","journal":"Journal of translational medicine","studyType":"Clinical Study"},{"pmid":"40682750","year":"2025","title":"An innovative machine learning-based QSAR approach for prediction and structural analysis of novel/repurposed acid ceramidase (ASAH1) inhibitors for glioblastoma therapy.","finding":"","journal":"Molecular diversity","studyType":"Clinical Study"},{"pmid":"40216001","year":"2025","title":"Improved apoptosis and mitochondrial dysfunction: the potential of carmofur-platinum nanoparticles.","finding":"","journal":"Biomedical materials (Bristol, England)","studyType":"Clinical Study"}],"tags":[{"label":"carmofur","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Acid ceramidase","category":"target"},{"label":"ASAH1","category":"gene"},{"label":"CYP2D6","category":"gene"},{"label":"MAPK3","category":"gene"},{"label":"L01BC04","category":"atc"},{"label":"Active","category":"status"},{"label":"Malignant tumor of colon","category":"indication"},{"label":"Antineoplastic Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"mifurol","offLabel":[],"synonyms":["1-hexylcarbamoyl-5-fluorouracil","carmofur","mifurol","yamaful"],"timeline":[],"brandName":"Mifurol","ecosystem":[{"indication":"Malignant tumor of colon","otherDrugs":[{"name":"cetuximab","slug":"cetuximab","company":"Imclone"},{"name":"fluorouracil","slug":"fluorouracil","company":"Spectrum Pharms"},{"name":"tipiracil","slug":"tipiracil","company":"Taiho Oncology Inc"},{"name":"trifluridine","slug":"trifluridine","company":"Monarch Pharms"}],"globalPrevalence":null}],"mechanism":{"target":"Acid ceramidase","targets":[{"gene":"ASAH1","source":"DrugCentral","target":"Acid ceramidase","protein":"Acid ceramidase"},{"gene":"CYP2D6","source":"DrugCentral","target":"Cytochrome P450 2D6","protein":"Cytochrome P450 2D6"},{"gene":"MAPK3","source":"DrugCentral","target":"Mitogen-activated protein kinase 3","protein":"Mitogen-activated protein kinase 3"},{"gene":"SQRDL","source":"DrugCentral","target":"Sulfide:quinone oxidoreductase, mitochondrial","protein":"Sulfide:quinone oxidoreductase, mitochondrial"}],"modality":"Small Molecule","drugClass":"carmofur","explanation":"Think of cancer cells like a city with a strong wall. Acid ceramidase is like a key that helps the cancer cells build and repair their wall, making them stronger. Mifurol blocks this key, making it harder for the cancer cells to grow and spread.","oneSentence":"Mifurol works by inhibiting the enzyme acid ceramidase, which plays a role in the development and progression of cancer cells.","technicalDetail":"Mifurol specifically binds to and inhibits the activity of acid ceramidase, a lysosomal enzyme involved in the hydrolysis of ceramides, which are important signaling molecules in cancer cell growth and survival."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/511","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CARMOFUR","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CARMOFUR","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:12:35.855798","biosimilars":[],"competitors":[{"drugName":"cytarabine","drugSlug":"cytarabine","fdaApproval":"1969-06-17","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fluorouracil","drugSlug":"fluorouracil","fdaApproval":"1962-04-25","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"gemcitabine","drugSlug":"gemcitabine","fdaApproval":"1996-05-15","patentExpiry":"Jun 28, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"capecitabine","drugSlug":"capecitabine","fdaApproval":"1998-04-30","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"azacitidine","drugSlug":"azacitidine","fdaApproval":"2004-05-19","patentExpiry":"May 14, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"decitabine","drugSlug":"decitabine","fdaApproval":"2006-05-02","genericCount":20,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"floxuridine","drugSlug":"floxuridine","fdaApproval":"1970-12-18","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"trifluridine","drugSlug":"trifluridine","fdaApproval":"1980-04-10","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"carmofur","indications":{"approved":[{"name":"Malignant tumor of colon","source":"DrugCentral","snomedId":363406005,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cytarabine","brandName":"cytarabine","genericName":"cytarabine","approvalYear":"1969","relationship":"same-class"},{"drugId":"fluorouracil","brandName":"fluorouracil","genericName":"fluorouracil","approvalYear":"1962","relationship":"same-class"},{"drugId":"gemcitabine","brandName":"gemcitabine","genericName":"gemcitabine","approvalYear":"1996","relationship":"same-class"},{"drugId":"capecitabine","brandName":"capecitabine","genericName":"capecitabine","approvalYear":"1998","relationship":"same-class"},{"drugId":"azacitidine","brandName":"azacitidine","genericName":"azacitidine","approvalYear":"2004","relationship":"same-class"},{"drugId":"decitabine","brandName":"decitabine","genericName":"decitabine","approvalYear":"2006","relationship":"same-class"},{"drugId":"floxuridine","brandName":"floxuridine","genericName":"floxuridine","approvalYear":"1970","relationship":"same-class"},{"drugId":"trifluridine","brandName":"trifluridine","genericName":"trifluridine","approvalYear":"1980","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07321613","phase":"","title":"Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2023-05-01","conditions":["Hepatocellular Cancer (HCC)"],"enrollment":545,"completionDate":"2025-06-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"010893","UNII":"HA82M3RAB2","CHEBI":"CHEBI:31360","INN_ID":"5042","UMLSCUI":"C0044401","ChEMBL_ID":"CHEMBL460499","KEGG_DRUG":"D01784","DRUGBANK_ID":"DB09010","PUBCHEM_CID":"2577","MESH_SUPPLEMENTAL_RECORD_UI":"C017367"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":163,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01BC04","allCodes":["L01BC04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025","pmid":"41235136","title":"PSORI-CM02 Restores Epidermal Differentiation in Psoriasis via the Gut Microbiota-Sphingolipid Axis.","journal":"Drug design, development and therapy"},{"date":"2025 Aug 12","pmid":"40705936","title":"Reproducibility of QM/MM Calculations for the SARS-CoV-2 Main Protease.","journal":"Journal of chemical theory and computation"},{"date":"2025 Jul 23","pmid":"40702551","title":"Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.","journal":"Journal of translational medicine"},{"date":"2025 Jul 19","pmid":"40682750","title":"An innovative machine learning-based QSAR approach for prediction and structural analysis of novel/repurposed acid ceramidase (ASAH1) inhibitors for glioblastoma therapy.","journal":"Molecular diversity"},{"date":"2025 Apr 23","pmid":"40216001","title":"Improved apoptosis and mitochondrial dysfunction: the potential of carmofur-platinum nanoparticles.","journal":"Biomedical materials (Bristol, England)"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mifurol, also known as Carmofur, is a small molecule drug that targets acid ceramidase. It is classified as a carmofur and is used to treat malignant tumors of the colon. The commercial status of Mifurol is unclear, and it is not known if it is patented or available as a generic medication. As a cancer treatment, Mifurol's safety considerations are critical, but specific details are not available. Further research is needed to understand its pharmacokinetic properties and clinical use.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}